Afschin Gandjour : Citation Profile


Are you Afschin Gandjour?

Frankfurt School of Finance and Management

4

H index

2

i10 index

40

Citations

RESEARCH PRODUCTION:

8

Articles

RESEARCH ACTIVITY:

   7 years (2005 - 2012). See details.
   Cites by year: 5
   Journals where Afschin Gandjour has often published
   Relations with other researchers
   Recent citing documents: 2.    Total self citations: 1 (2.44 %)

MORE DETAILS IN:
ABOUT THIS REPORT:

   Permalink: http://citec.repec.org/pga659
   Updated: 2021-01-02    RAS profile:    
   Missing citations? Add them    Incorrect content? Let us know

Relations with other researchers


Works with:

Authors registered in RePEc who have co-authored more than one work in the last five years with Afschin Gandjour.

Is cited by:

Brouwer, Werner (6)

Devlin, Nancy (1)

Gyrd-Hansen, Dorte (1)

Johar, Meliyanni (1)

Towse, Adrian (1)

Cites to:

Claxton, Karl (3)

Philipson, Tomas (2)

Sen, Amartya (2)

Jena, Anupam (2)

Straume, Odd Rune (1)

Mechoulan, Stéphane (1)

Dranove, David (1)

van Ypersele, Tanguy (1)

Gallini, Nancy (1)

Norton, Edward (1)

Arrow, Kenneth (1)

Main data


Where Afschin Gandjour has published?


Journals with more than one article published# docs
Health Policy2
Health Care Management Science2
Journal of Health Economics2

Recent works citing Afschin Gandjour (2020 and 2019)


YearTitle of citing document
2019Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design. (2019). Rai, Sukhvir ; Ward, Thomas ; Sugrue, Daniel M ; McEwan, Phil. In: PharmacoEconomics. RePEc:spr:pharme:v:37:y:2019:i:12:d:10.1007_s40273-019-00835-z.

Full description at Econpapers || Download paper

2019Future Costs in Cost-Effectiveness Analyses: Past, Present, Future. (2019). Vries, Linda M. In: PharmacoEconomics. RePEc:spr:pharme:v:37:y:2019:i:2:d:10.1007_s40273-018-0749-8.

Full description at Econpapers || Download paper

Works by Afschin Gandjour:


YearTitleTypeCited
2011A new prize system for drug innovation In: Health Policy.
[Full Text][Citation analysis]
article0
2007A national hypertension treatment program in Germany and its estimated impact on costs, life expectancy, and cost-effectiveness In: Health Policy.
[Full Text][Citation analysis]
article8
2005Does prevention save costs?: Considering deferral of the expensive last year of life In: Journal of Health Economics.
[Full Text][Citation analysis]
article11
2010The additive utility assumption of the QALY model revisited In: Journal of Health Economics.
[Full Text][Citation analysis]
article1
2012Presenting Germany’s drug pricing rule as a cost-per-QALY rule In: Health Care Management Science.
[Full Text][Citation analysis]
article2
2006Cost-effectiveness of referrals to high-volume hospitals: An analysis based on a probabilistic Markov model for hip fracture surgeries In: Health Care Management Science.
[Full Text][Citation analysis]
article4
2008Mutual dependency between capabilities and functionings in Amartya Sen’s capability approach In: Social Choice and Welfare.
[Full Text][Citation analysis]
article2
2006Consumption costs and earnings during added years of life ‐ a reply to Nyman In: Health Economics.
[Full Text][Citation analysis]
article12

CitEc is a RePEc service, providing citation data for Economics since 2001. Sponsored by INOMICS. Last updated November, 2 2020. Contact: CitEc Team